Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2020 Jul 10;24(1):140–149. doi: 10.1038/s41391-020-0254-y

Fig. 3. Detection of human CD8 (yellow), CD4 (green), PCK (cian), FOXP3 (red), Ki67 (magenta) and PD-L1 (orange) in FFPE prostate cancer biopsies by IHC-IF.

Fig. 3

a Quantification of PD-L1 (left), CD8+ (middle) and CD4+ (right) in multiplex images of early responders (ER) and late responders (LR) patients; Three patients per group. b Representative Multiplex IHC images of patients 1 and 3 (PT-01 and PT-03) at T0 (Diagnostic biopsy), T1 (Specimen collected after two cycles of nivolumab, and prior to HDR#1) and T3 (Specimen collected after 4 cycles of nivolumab and four weeks after HDR#1, but prior to HDR#2).